PharmaCyte Biotech Inc (PMCB)
2.20
+0.08
(+3.77%)
USD |
NASDAQ |
Apr 18, 16:00
2.18
-0.02
(-0.91%)
After-Hours: 20:00
PharmaCyte Biotech Debt to Equity Ratio
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| October 31, 2012 | -0.2045 |
| July 31, 2012 | -0.3077 |
| April 30, 2012 | -1.231 |
| January 31, 2012 | -1.095 |
| October 31, 2011 | -0.9963 |
| July 31, 2011 | -0.9848 |
| April 30, 2011 | -0.8691 |
| January 31, 2011 | -1.070 |
| October 31, 2010 | -1.116 |
| July 31, 2010 | -1.141 |
| April 30, 2010 | -0.9722 |
| January 31, 2010 | 1.621 |
| October 31, 2009 | 0.7925 |
| July 31, 2009 | 0.7493 |
| April 30, 2009 | 0.7936 |
| January 31, 2009 | 0.00 |
| October 31, 2008 | 0.00 |
| Date | Value |
|---|---|
| July 31, 2008 | 0.00 |
| April 30, 2008 | 0.00 |
| January 31, 2008 | 0.00 |
| October 31, 2007 | 0.00 |
| July 31, 2007 | 0.00 |
| April 30, 2007 | 0.00 |
| January 31, 2007 | 0.1404 |
| October 31, 2006 | 0.1322 |
| July 31, 2006 | 0.1251 |
| April 30, 2006 | 0.1151 |
| January 31, 2006 | -1.005 |
| October 31, 2005 | -0.852 |
| July 31, 2005 | -0.889 |
| April 30, 2005 | -0.9868 |
| January 31, 2005 | -1.374 |
| October 31, 2004 | -1.731 |
| July 31, 2004 | -5.787 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.00 |
| IGC Pharma Inc | 0.0152 |
| NovaBay Pharmaceuticals Inc | 0.3431 |
| Protalix BioTherapeutics Inc | 0.6033 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 71.36M |
| Total Liabilities (Quarterly) | 22.47M |
| Shareholders Equity (Quarterly) | 48.89M |